Answers are grounded in this paper and cite their sources.
Background: Previous studies have proven that Korean Traditional Medical substance HangAmDan-B1 (HAD-B1) is safe and effective in treating lung cancer. According to those research, long term and high dosage administration of HAD-B1 (13 week, higher than 2000 mg/kg), and its combined administration with Afatinib did not affect the therapeutic effect of Afatinib, and showed no drug tolerance. In vivo and in vitro studies also showed that HAD-B1 was found to be safe as it did not affect normal cells. Based on those results, this clinical trial aims to evaluate the safety and pharmacokinetics by oral administration of HAD-B1 in healthy male volunteers. Methods: Fifteen healthy male volunteers will be recruited for the study. Sample size for this phase 1 clinical trial. Subjects will be pre-examined within 4 weeks prior to the first dosing day to evaluate the compatibility. On day 0, participants will be admitted around 4 PM and will be fasting from 10 PM except for the water intake. On the dosing day, participants will take HAD-B1 at 8 AM on an empty stomach (1.944 g/day). Blood sample will be drawn at pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 48 hours. Area under the curve will be expressed in linear and log/linear graphs. Pharmacokinetic analysis will be non-compartment analysis using Phoenix WinNonlin (Pharsight, CA) software package. Discussion: This study investigates the safety and pharmacokinetics of HAD-B1 as it is already proven to be safe and effective according to the previous studies. The results from this clinical trial are expected to provide strict and objective evidences of the efficacy and safety of the formula HAD-B1 for patients with lung cancer.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: